Preclinical characterization and clinical development of ILARIS® (canakinumab) for the treatment of autoinflammatory diseases

Current Opinion in Chemical Biology

Volumn 32, Issue , 2016, Pages 1-9

  Gram, Hermann ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ANTIGEN ANTIBODY REACTION; AUTOINFLAMMATORY DISEASE; COMPARTMENT MODEL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IC50; IN VITRO STUDY; IN VIVO STUDY; MUCKLE WELLS SYNDROME; NONHUMAN; PHARMACODYNAMICS; RARE DISEASE; RELAPSE; REVIEW; SCHNITZLER SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMICAL STRUCTURE; HALF LIFE TIME; INFLAMMATION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); X RAY DIFFRACTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; HALF-LIFE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; X-RAY DIFFRACTION;

EID: 84950990910     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2015.12.003     Document Type: Review

References (53)

1. Lainka E., Neudorf U., Lohse P., Timmann C., Bielak M., Stojanov S., Huss K., von Kries R., Niehues T. Analysis of cryopyrin-associated periodic syndromes (CAPS) in German children: epidemiological, clinical and genetic characteristics. Klin Pädiatrie 2010, 222:356-361.
2. Simon A., van der Meer J.W.M. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 2007, 292:R86-R98.
3. Hoffman H.M., Mueller J.L., Broide D.H., Wanderer A.A., Kolodner R.D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305.
4. Aksentijevich I., Nowak M., Mallah M., Chae J.J., Watford W.T., Hofmann S.R., Stein L., Russo R., Goldsmith D., Dent P., et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002, 46:3340-3348.
5. Aganna E., Martinon F., Hawkins P.N., Ross J.B., Swan D.C., Booth D.R., Lachmann H.J., Bybee A., Gaudet R., Woo P., et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002, 46:2445-2452.
6. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
7. Rathinam V.A.K., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat Immunol 2012, 13:332-333.
8. Martinon F., Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004, 117:561-574.
9. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., Anderson J.P., Wanderer A.A., Firestein G.S. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
10. Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348:2583-2584.
11. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005, 23:1117-1125.
12. Fishwild D.M., O'Donnell S.L., Bengoechea T., Hudson D.V., Harding F., Bernhard S.L., Jones D., Kay R.M., Higgins K.M., Schramm S.R., et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996, 14:845-851.
13. Alten R., Gram H., Joosten L.A., van den Berg W.B., Sieper J., Wassenberg S., Burmester G., van Riel P., Diaz-Lorente M., Bruin G.J.M., et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R67.
14. Rondeau J.M., Ramage P., Zurini M., Gram H. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs 2015, 7:1151-1160.
15. Wang D., Zhang S., Li L., Liu X., Mei K., Wang X. Structural insights into the assembly and activation of IL-1β with its receptors. Nat Immunol 2010, 11:905-911.
16. Thomas C., Bazan J.F., Garcia K.C. Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol 2012, 19:455-457.
17. Neuberta R.T., Webb J.R., Neubert D. Feasibility of human trials to assess developmmental immunotoxicity, and some comparison with data on New World monkeys. Hum Exp Toxicol 2002, 21:543-567.
18. Lachmann H.J., Lowe P., Felix S.D., Rordorf C., Leslie K., Madhoo S., Wittkowski H., Bek S., Hartmann N., Bosset S., et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036.
19. Chakraborty A., Tannenbaum S., Rordorf C., Lowe P.J., Floch D., Gram H., Roy S. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet 2012, 51:e1-e18.
20. Reimers J., Wogensen L.D., Welinder B., Hejnaes K.R., Poulsen S.S., Nilsson P., Nerup J. The pharmacokinetics, distribution and degradation of human recombinant interleukin 1 beta in normal rats. Scand J Immunol 1991, 34:597-610.
21. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., Gitton X., Widmer A., Patel N., Hawkins P.N. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
22. Kuemmerle-Deschner J.B., Hachulla E., Cartwright R., Hawkins P.N., Tran T.A., Bader-Meunier B., Hoyer J., Gattorno M., Gul A., Smith J., et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011, 70:2095-2102.
23. Caorsi R., Lepore L., Zulian F., Alessio M., Stabile A., Insalaco A., Finetti M., Battagliese A., Martini G., Bibalo C., et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther 2013, 15:R33.
24. Russo R., Melogomes S., Lachmann H.J., Wynne K., Rajput K., Eleftheriou D., Edelsten C., Hawkins P.N., Brogan P.A. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology (United Kingdom) 2014, 53:665-670.
25. Marsaud C., Marie I., Koné-Paut I. Longterm followup of quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab, an anti-interleukin 1β monoclonal antibody. J Rheumatol 2014, 41:1721-1722.
26. Fonnesu C., Cerquaglia C., Giovinale M., Curigliano V., Verrecchia E., de Socio G., La Regina M., Gasbarrini G., Manna R. Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine 2009, 76:227-233.
27. Chae J.J., Wood G., Masters S.L., Richard K., Park G., Smith B.J., Kastner D.L. The B30.2 domain of pyrin, the Familial Mediterranean Fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006, 103:9982-9987.
28. Park H., Bourla A.B., Kastner D.L., Colbert R.A., Siegel R.M. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 2012, 12:570-580.
29. Normand S., Massonnet B., Delwail A., Favot L., Cuisset L., Grateau G., Morel F., Silvain C., Lecron J.-C. Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation. Eur Cytokine Netw 2009, 20:101-107.
30. Papers J.B.C., Doi M., Burgh R., Van Der, Pervolaraki K., Turkenburg M., Waterham H.R., Frenkel J. Unprenylated RhoA contributes to IL-1b hypersecretion in mevalonate kinase deficiency odel through stimulation of Rac1 activity. J Biol Chem 2014, 289:27757-27765.
31. van der Burgh R., Ter Haar N.M., Boes M.L., Frenkel J. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol 2013, 147:197-206.
32. Başaran Ö., Uncu N., Çelikel B.A., Taktak A., Gür G., Cakar N. Interleukin-1 targeting treatment in Familial Mediterranean Fever: an experience of pediatric patients. Mod Rheumatol 2015, 25:621-624.
33. Curtis C.D., Fox C.C. Treatment of adult hyper-IgD syndrome with canakinumab. J Allergy Clin Immunol Pract 2015, 3:817-818.
34. Eroglu F.K., Beşbaş N., Topaloglu R., Ozen S. Treatment of colchicine-resistant Familial Mediterranean Fever in children and adolescents. Rheumatol Int 2015, 35:1733-1737.
35. Kostjukovits S., Kalliokoski L., Antila K., Korppi M. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. Eur J Pediatr 2015, 174:707-714.
36. La Torre F., Muratore M., Vitale A., Moramarco F., Quarta L., Cantarini L. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int 2015, 35:1943-1947.
37. Cetin P., Sari I., Sozeri B., Cam O., Birlik M., Akkoc N., Onen F., Akar S. Efficacy of interleukin-1 targeting treatments in patients with Familial Mediterranean Fever. Inflammation 2014, 38:27-31.
38. Lopalco G., Rigante D., Vitale A., Frediani B., Iannone F., Cantarini L. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol 2015, 34:807-809.
39. Gattorno M., Lachmann H.J. Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome. Arthritis Rheum 2012, 64:s322.
40. Gul A., Ozdogan H., Erer B., Ugurlu S., Kasapcopur O., Davis N., Sevgi S. Efficacy and safety of canakinumab in adolescents and adults with colchicine resistant Familial Mediterranean Fever. Arthritis Res Ther 2015, 17:243.
41. de Koning H.D., Bodar E.J., Simon A., van der Hilst J.C.H., Netea M.G., van der Meer J.W.M. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis 2006, 65:542-544.
42. de Koning H.D., Schalkwijk J., van der Ven-Jongekrijg J., Stoffels M., van der Meer J.W.M., Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann Rheum Dis 2013, 72:1634-1638.
43. de Koning H.D., Schalkwijk J., Stoffels M., Jongekrijg J., Jacobs J.F.M., Verwiel E., Koenen H.J.P.M., Preijers F., Holzinger D., Joosten I., et al. The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome. Arthritis Res Ther 2015, 17:187.
44. Mellins E.D., Macaubas C., Grom A.A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011, 7:416-426.
45. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., Cuttica R., Ravelli A., Schneider R., Woo P., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2385-2395.
46. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C., Bossuyt X., Boutten A., Bienvenu J., Duquesne A., et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011, 70:747-754.
47. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G., Brik R., McCann L., Kasapcopur O., Rutkowska-Sak L., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2396-2406.
48. Canna S.W., de Jesus A.A., Gouni S., Brooks S.R., Marrero B., Liu Y., DiMattia M.A., Zaal K.J.M., Sanchez G.A.M., Kim H., et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 2014, 46:1140-1146.
49. Romberg N., Al Moussawi K., Nelson-Williams C. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 2014, 46:1135-1139.
50. Cavalli G., Dinarello C.A. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology 2015, 54:2134-2144.
51. Ridker P.M., Lüscher T.F. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014, 35:1782-1791.
52. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162:597-605.
53. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat Rev Immunol 2010, 10:210-215.